Brief: Pure Biologics Signs Deal For Subsidy With Poland's Medical Research Agency
09/03/2023 16:19
March 9 (Reuters) - Pure Biologics SA PUR1.WA :
* SIGNS DEAL FOR SUBSIDY WITH POLAND'S MEDICAL RESEARCH
AGENCY
* SUBSIDY FOR 'A PHASE 1 STUDY TO INVESTIGATE SAFETY,
TOLERABILITY
AND EFFICACY OF BISPECIFIC COMPOUND IN SUBJECTS WITH ADVANCED
SOLID TUMORS' PROJECT
* TOTAL PROJECT COST AT 48.9 MILLION ZLOTYS
* RECOMMENDED VALUE OF SUBSIDY AT 32.4 MILLION ZLOTYS
* PROJECT TO BE IMPLEMENTED IN YEARS 2022-2026
Source text for Eikon: ID:nEM6GZC0Qa
Further company coverage: PUR1.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Multiqure SA
See all newsBrief: Selvita To Expand Its Operations Through New Biological Drug Business
Brief: Pure Biologics FY Net Loss Widens To 25.6 Mln Zlotys
Brief: Pure Biologics Signs Term Sheet With ACRX Investments On Potential Financing
Brief: Pure Biologics Signs Deal For Subsidy With Poland's Medical Research Agency
Brief: Pure Biologics To Seek Extra Financing For PB003 And PB004 Projects